BIOGEN INC. (BIIB) Current Ratio
- Current ratio · latest quarter: Value 3.06×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.06× | Current assets / current liabilities. $9.19B ÷ $3.00B ≈ 3.06× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 9.19B USD | Assets, Current |
| Current obligations | 3.00B USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 900.00M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 1.95B USD | Inventory, Net |
| Payables | 358.50M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $9.19B | $3.00B | (m) | $900.00M | (m) | $1.95B | $358.50M | (m) | 3.06× |
| 2025-12-31 | $8.97B | $3.35B | (m) | $807.20M | (m) | $2.17B | $432.00M | (m) | 2.68× |
| 2025-09-30 | $8.94B | $3.29B | (m) | $97.60M | (m) | $2.21B | $413.10M | (m) | 2.72× |
| 2025-06-30 | $7.97B | $3.18B | (m) | (m) | (m) | $2.27B | $408.40M | (m) | 2.50× |
| 2025-03-31 | $7.63B | $5.30B | (m) | (m) | (m) | $2.27B | $391.50M | (m) | 1.44× |
| 2024-12-31 | $7.46B | $5.53B | (m) | $0.00 | $1.40B | $2.46B | $424.20M | (m) | 1.35× |
| 2024-09-30 | $6.83B | $5.42B | (m) | (m) | (m) | $2.47B | $422.70M | (m) | 1.26× |
| 2024-06-30 | $7.11B | $3.11B | (m) | (m) | (m) | $2.51B | $354.50M | (m) | 2.29× |
| 2024-03-31 | $6.76B | $3.22B | (m) | (m) | (m) | $2.52B | $387.00M | (m) | 2.10× |
| 2023-12-31 | $6.86B | $3.43B | (m) | (m) | $1.66B | $2.53B | $403.30M | (m) | 2.00× |
| 2023-09-30 | $8.45B | $5.02B | (m) | $0.00 | (m) | $2.98B | $440.10M | (m) | 1.68× |
| 2023-06-30 | $10.43B | $3.19B | (m) | $3.46B | (m) | $1.33B | $445.40M | (m) | 3.27× |
| 2023-03-31 | $9.76B | $3.01B | (m) | $2.14B | $1.63B | $1.28B | $491.20M | (m) | 3.24× |
| 2022-12-31 | $9.79B | $3.27B | (m) | $1.47B | $1.71B | $1.34B | $491.50M | (m) | 2.99× |
| 2022-09-30 | $9.77B | $3.93B | (m) | $1.24B | $1.57B | $1.38B | $383.20M | (m) | 2.49× |
| 2022-06-30 | $9.74B | $5.02B | (m) | $2.15B | $1.57B | $1.29B | $434.80M | (m) | 1.94× |
| 2022-03-31 | $7.92B | $3.95B | (m) | $2.00B | $1.63B | $1.22B | $398.70M | (m) | 2.01× |
| 2021-12-31 | $7.86B | $4.30B | (m) | $1.54B | $1.55B | $1.35B | $589.20M | (m) | 1.83× |
| 2021-09-30 | $7.16B | $4.21B | (m) | $1.41B | $1.72B | $1.35B | $427.90M | (m) | 1.70× |
| 2021-06-30 | $7.18B | $3.35B | (m) | $1.31B | $1.69B | $1.25B | $375.30M | (m) | 2.15× |
| 2021-03-31 | $6.72B | $3.17B | (m) | $1.32B | $1.85B | $1.17B | $430.40M | (m) | 2.12× |
| 2020-12-31 | $6.89B | $3.74B | (m) | $1.28B | $1.91B | $1.07B | $454.90M | (m) | 1.84× |
| 2020-09-30 | $7.84B | $3.80B | (m) | $1.35B | $2.02B | $1.03B | $398.40M | (m) | 2.06× |
| 2020-06-30 | $8.49B | $3.45B | (m) | $1.94B | $2.13B | $952.70M | $383.90M | (m) | 2.46× |
| 2020-03-31 | $8.01B | $4.64B | (m) | $1.27B | $2.09B | $858.80M | $389.00M | (m) | 1.73× |
| 2019-12-31 | $8.38B | $4.86B | (m) | $1.56B | $1.88B | $804.20M | $530.80M | (m) | 1.72× |
| 2019-09-30 | $8.45B | $4.43B | $2.34B | $2.09B | $1.93B | $751.80M | $382.20M | (m) | 1.91× |
| 2019-06-30 | $7.91B | $3.21B | $1.72B | $1.23B | $1.96B | $776.70M | $377.10M | (m) | 2.46× |
| 2019-03-31 | $8.94B | $3.15B | $2.24B | $1.67B | $2.09B | $770.20M | $378.00M | (m) | 2.84× |
| 2018-12-31 | $7.64B | $3.30B | $1.22B | $2.31B | $1.96B | $929.90M | $370.50M | (m) | 2.32× |
| 2018-09-30 | $8.72B | $3.17B | $2.39B | $2.04B | $2.02B | $916.60M | $342.30M | (m) | 2.75× |
| 2018-06-30 | $7.43B | $3.15B | $1.25B | $1.97B | $1.95B | $931.70M | $295.70M | (m) | 2.36× |
| 2018-03-31 | $10.20B | $3.15B | $4.11B | $1.81B | $1.94B | $890.80M | $345.80M | (m) | 3.23× |
| 2017-12-31 | $7.87B | $3.37B | $1.57B | $2.12B | $1.79B | $902.70M | $395.50M | (m) | 2.34× |
| 2017-09-30 | $7.57B | $3.45B | $1.55B | $1.96B | $1.57B | $1.01B | $298.70M | (m) | 2.19× |
| 2017-06-30 | $7.11B | $3.38B | $1.17B | $1.72B | $1.63B | $936.50M | $330.30M | (m) | 2.10× |
| 2017-03-31 | $6.86B | $2.99B | $924.00M | $1.96B | $1.50B | $921.60M | $316.40M | (m) | 2.29× |
| 2016-12-31 | $8.73B | $3.42B | $2.33B | $2.57B | $1.44B | $1.00B | $279.80M | (m) | 2.55× |
| 2016-09-30 | $8.09B | $2.50B | $2.08B | $2.23B | $1.47B | $1.01B | $274.00M | (m) | 3.24× |
| 2016-06-30 | $7.45B | $2.52B | $1.36B | $2.43B | $1.29B | $996.40M | $225.90M | (m) | 2.96× |
| 2016-03-31 | $7.20B | $2.78B | $1.13B | $2.45B | $1.40B | $964.60M | $271.30M | (m) | 2.59× |
| 2015-12-31 | $6.70B | $2.58B | $1.31B | $2.12B | $1.23B | $893.40M | $267.40M | (m) | 2.60× |
| 2015-09-30 | $9.27B | $2.63B | $4.09B | $1.75B | $1.33B | $918.92M | $251.23M | (m) | 3.52× |
| 2015-06-30 | $5.62B | $2.56B | $1.28B | $1.09B | $1.31B | $865.74M | $282.70M | (m) | 2.20× |
| 2015-03-31 | $5.26B | $1.95B | $1.48B | $673.95M | $1.39B | $825.35M | $236.13M | (m) | 2.70× |
| 2014-12-31 | $4.54B | $2.22B | $1.20B | $640.50M | $1.29B | $804.00M | $229.20M | (m) | 2.04× |
| 2014-09-30 | $4.37B | $1.94B | $1.19B | $675.07M | $1.09B | $753.06M | $233.63M | (m) | 2.25× |
| 2014-06-30 | $3.93B | $1.92B | $863.20M | $709.87M | $1.00B | $715.93M | $224.93M | (m) | 2.05× |
| 2014-03-31 | $3.53B | $1.59B | $828.60M | $431.61M | $1.02B | $672.75M | $212.81M | (m) | 2.21× |
| 2013-12-31 | $3.18B | $1.76B | $602.56M | $620.17M | $824.41M | $659.00M | $219.91M | (m) | 1.81× |
| 2013-09-30 | $2.64B | $1.52B | $427.81M | $240.88M | $891.40M | $614.48M | $166.71M | (m) | 1.74× |
| 2013-06-30 | $2.52B | $1.30B | $392.51M | $275.16M | $861.46M | $570.39M | $163.09M | (m) | 1.93× |
| 2013-03-31 | $5.33B | $1.28B | $663.30M | $0.00 | $753.61M | $506.56M | $165.21M | (m) | 4.16× |
| 2012-12-31 | $3.24B | $1.66B | $570.72M | $1.13B | $686.85M | $447.37M | $204.00M | (m) | 1.96× |
| 2012-09-30 | $3.06B | $1.52B | $451.72M | $1.15B | $661.52M | $392.94M | $157.42M | (m) | 2.01× |
| 2012-06-30 | $2.87B | $1.43B | $456.81M | $949.24M | $683.84M | $362.94M | $159.15M | (m) | 2.00× |
| 2012-03-31 | $2.68B | $1.34B | $298.14M | $978.47M | $684.24M | $337.62M | $173.33M | (m) | 2.00× |
| 2011-12-31 | $2.98B | $912.89M | $514.54M | $1.18B | $584.60M | $326.84M | $186.45M | (m) | 3.26× |
| 2011-09-30 | $2.84B | $885.35M | $575.14M | $944.38M | $581.05M | $310.93M | $159.20M | (m) | 3.20× |
| 2011-06-30 | $2.69B | $954.33M | $697.53M | $629.22M | $666.96M | $308.25M | $170.75M | (m) | 2.82× |
| 2011-03-31 | $2.63B | $978.85M | $790.67M | $437.87M | $687.61M | (m) | $159.14M | (m) | 2.69× |
| 2010-12-31 | $2.54B | $1.05B | $759.60M | $448.15M | $605.33M | $289.07M | $162.53M | (m) | 2.42× |
| 2010-09-30 | $2.13B | $824.48M | $626.76M | $197.84M | $616.70M | (m) | $143.70M | (m) | 2.58× |
| 2010-06-30 | $2.26B | $755.66M | $720.96M | $248.71M | $548.89M | $267.88M | $144.48M | (m) | 2.98× |
| 2010-03-31 | $2.41B | $682.33M | $639.56M | $513.12M | $560.78M | $280.04M | $121.36M | (m) | 3.53× |
| 2009-12-31 | $2.48B | $714.94M | $581.89M | $681.84M | $551.21M | (m) | $118.53M | (m) | 3.47× |
| 2009-09-30 | $2.57B | $721.37M | $585.79M | $821.89M | $551.00M | $278.69M | $108.55M | (m) | 3.57× |
| 2009-06-30 | $2.74B | $803.93M | $786.80M | $836.27M | $511.29M | $268.53M | (m) | (m) | 3.41× |
| 2008-12-31 | $2.46B | $923.22M | $622.38M | $719.59M | $446.67M | $263.60M | $107.42M | (m) | 2.66× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |